Loading...
Printed on 7/21/2026
For informational purposes only. This is not medical advice.
The Quick Dementia Rating System (QDRS) is an informant-completed scale that captures cognitive, behavioral, and functional changes to provide rapid dementia severity staging context. It is useful in clinic workflows where brief caregiver-informed assessment is needed.
Formula: QDRS total is a summed informant-rated score, range 0-30.
Save your results with a free account
Keep a history of calculations, favorite tools, and access your dashboard anytime.
QDRS must be completed by a caregiver or family member who has direct, regular contact with the patient—ideally several hours per week over the past month. The informant rates the patient's cognitive and functional abilities as observed during daily life over the preceding 4 weeks, not during a single clinical visit. An uninformed or infrequent contact will produce unreliable scores. The 4-week reference window is deliberate and should be stated explicitly to the informant before they begin.
The informant rates the patient across multiple cognitive and functional domains including memory and orientation, judgment and problem-solving, household activities and self-care, and behavioral and neuropsychiatric changes. Each domain is rated 0 (no impairment), 0.5 (questionable), 1 (very mild), 2 (moderate), or 3 (severe), with the total reflecting the summed burden across domains (range 0–30). QDRS can be self-administered by the caregiver on paper or digital form before the clinical visit.
Interpret the QDRS total: 0–2 = no/questionable impairment; 3–8 = very mild dementia; 9–15 = mild dementia; 16–22 = moderate dementia; 23–30 = severe dementia. Pair QDRS with an objective performance-based cognitive test (MoCA or MMSE) when possible—informant-rated and performance-based tools provide complementary data. Serial QDRS scores at 6–12 month intervals quantify disease progression and trigger care plan adjustments when a 2-point or greater increase is detected.
Neurologists, geriatricians, memory clinic nurses
QDRS provides rapid dementia severity staging when full neuropsychological testing is unavailable or impractical at the initial consultation. By completing QDRS before the appointment, the caregiver provides structured information that orients the clinician to the patient's functional and cognitive severity tier before any formal testing begins. Clinicians can use QDRS alongside the MoCA or MMSE to triangulate between objective performance and caregiver-observed real-world function—a combination that captures both the cognitive floor performance and the day-to-day functional impact that may not be apparent during a structured test.
General practitioners, nurse practitioners, primary care teams
Most dementia diagnoses are made or managed in primary care. QDRS allows primary care clinicians to quantify severity at each visit without requiring a full neuropsychological battery. A baseline score at the time of diagnosis and repeated scores at 6-month intervals provide an evidence-based trajectory that supports referral decisions, driving questions for specialist appointments, and documentation of clinical necessity for medications such as cholinesterase inhibitors. QDRS scores above 15 (mild-to-moderate range) typically warrant specialist review and consideration of pharmacological management.
Geriatricians, neurologists, memory clinics, primary care
Dementia progression is gradual and often difficult to distinguish from normal variation at any single visit. Serial QDRS scores—administered at every 6-month follow-up visit using the same informant whenever possible—create a longitudinal severity record that makes progression visible across consultations. An increase of 2 or more QDRS points over 6 months is clinically meaningful and warrants medication review, care plan escalation, and re-evaluation of the caregiver's support needs. The QDRS trajectory also documents the clinical course for insurance prior authorizations and care funding applications.
Clinicians providing dementia counseling, social workers, dementia care specialists
Following a dementia diagnosis, families often struggle to understand where their loved one sits on the severity spectrum and what to expect in the coming months and years. QDRS provides a structured framework that clinicians can use to explain current severity in concrete functional terms—relating the score to what the patient can and cannot do in daily life. Showing a caregiver that their loved one's QDRS score of 12 places them in the mild dementia range helps contextualize prognosis, plan for near-term care transitions, and set realistic expectations about the trajectory of cognitive and functional decline.
Care home physicians, nursing home assessment teams
For residents admitted to a care home with a known or suspected dementia diagnosis, QDRS provides a rapid baseline cognitive-functional severity staging on admission. This baseline score enables the care team to understand the resident's starting functional profile, set appropriate care goals, and identify the level of supervision and assistance required. Serial QDRS scores during the first 6–12 months post-admission document adjustment and progression, support staffing decisions, and provide objective evidence for care plan reviews, family meetings, and funding justification.
Clinical researchers, trial coordinators, epidemiologists
QDRS was designed to correlate closely with the Clinical Dementia Rating (CDR) scale, the gold standard for dementia severity staging in research, making it a practical tool for cohort stratification when full CDR administration is not feasible. Researchers use QDRS to screen potential trial participants, stratify cohorts by baseline severity, and measure change over time in longitudinal studies. Its informant-based design is particularly valuable in cohorts where patient performance-based testing is unreliable due to severe cognitive impairment, sensory limitations, or language barriers.
QDRS requires an informant who has direct, regular contact with the patient—ideally several hours per week over the past month. Scores from infrequent contacts or distant relatives who rely on phone updates are unreliable and should be documented as such in the clinical record.
The 4-week reference window is deliberate and should be explicitly communicated to the caregiver before they complete QDRS. Ask them to rate typical behavior over the past month, not their best or worst days, and not their function from years ago.
QDRS can be distributed to caregivers to complete in the waiting room or at home before the appointment, saving consultation time and allowing the informant to consider their answers without time pressure.
Pair QDRS with an objective cognitive test (MoCA or MMSE) whenever feasible. The combination of informant-rated real-world function (QDRS) and performance-based cognitive testing (MoCA/MMSE) provides stronger clinical characterization than either tool alone—discordance between them may indicate early functional decline, caregiver stress distortion, or pseudodementia.
Use the same caregiver informant across serial assessments whenever possible. Switching informants between visits introduces variability that can mimic or mask true disease progression—always document who completed the QDRS.
A QDRS increase of 2 or more points over 6 months warrants a structured response: medication review, care plan update, safety assessment for driving and independent living, and re-evaluation of the caregiver's support needs and burnout risk.
QDRS scores are staging severity tools, not etiology-specific. A score of 12 could reflect Alzheimer's disease, Lewy body dementia, vascular dementia, or frontotemporal dementia equally. Do not use QDRS to infer dementia type—use it alongside clinical history, neuroimaging, and biomarkers for diagnosis.
Concurrent use of the GDS-15 or PHQ-9 helps distinguish cognitive-functional impairment from depressive pseudodementia. Depressive pseudodementia can produce high QDRS scores that improve substantially with antidepressant treatment—screening for depression is essential at every dementia assessment.
QDRS was developed and validated by Galvin (Alzheimer's & Dementia, 2015) with strong correlation to the Clinical Dementia Rating (CDR) scale across memory clinic cohorts. Validation studies demonstrate sensitivity and specificity above 90% for CDR-equivalent staging. The scale is informant-dependent and performs best when completed by a caregiver with regular, direct contact with the patient. It is used clinically in memory clinics, primary care, and long-term care settings as a rapid severity staging and monitoring tool.
Higher QDRS totals indicate greater severity signal and support intensified cognitive-functional follow-up.
Use when informant input is available and rapid dementia severity context is needed.
Depends on informant reliability and may be influenced by caregiver stress or limited contact.
Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.
April 21, 2026 · v1.0.0
Added QDRS trust metadata fields and initial changelog record.
A 26-item informant-based cognitive decline screen summarized as a 1.0-5.0 mean score.
OpenGeriatricsScreen for cognitive impairment using the 8-item AD8 informant interview (score 0-8).
OpenGeriatricsInformant-rated everyday cognition decline scale summarized by mean score across 12 items.
OpenGeriatricsClassify dementia severity with the Clinical Dementia Rating global stage (0, 0.5, 1, 2, 3).
Open